Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete...(ients who achieved CR in the Phase 3 tri...),Health

Date:12/10/2007

ients who achieved CR in the Phase 3 trial. Previously, a survival benefit had been demonstrated only in CR patients who were prospectively stratified prior to randomization as being "non-refractory" to chemotherapy using a standard definition. (The prior data can be accessed at: http://www.genta.com/index.php?option=com_content&task=view&id=60&Itemid=73 &CI D=44&SHID=&COID=). (To view this Web site please cut and paste the URL into your browser.) The new data show that this superior survival benefit for Genasense-treated patients extends to all patients who achieved CR/nPR. These data are presented in the table below.

Survival Genasense/Flu/Cy Flu/Cy p-value

1 year 20 8 0.016

2 years 17 8 0.06

3 years 16 4 0.005

4 years 12 2 0.006

Safety

Grade 3 or Grade 4 adverse events that occurred during treatment or within 30 days from last treatment in an increased percentage of patients in the Genasense group included, but were not limited to, thrombocytopenia, nausea, and intravenous-catheter complications. Adverse events resulted in discontinuation of therapy in an equal percentage of patients in both groups. Nine patients in the Genasense group and 5 patients in the chemotherapy-alone group had adverse events that resulted in death, including two patients in the Genasense group who died from complications associated with tumor lysis and infusion-related reactions.

A scientific report of the safety and efficacy findings from this study was published earlier this year in the Journal of Clinical Oncology (25:1114, 2007).

Regulatory History of Genasense in CLL

Genta
'/>"/>

SOURCE Genta Incorporated Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy